OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Roland on the Utility of Neoadjuvant Immune-Checkpoint Blockade in Liposarcoma

March 5th 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Dr Phillips on Unmet Needs in Patients With Relapsed/Refractory MCL

March 5th 2024

Tycel Phillips, MD, discusses unmet needs for patients with relapsed/refractory mantle cell lymphoma.

Dr Olson on the FDA Approval of Lifileucel for Advanced Melanoma

March 5th 2024

Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.

Dr Gross on the Safety of Neoadjuvant Cemiplimab in Stage II/IV CSCC

March 5th 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Blackwood on the Significance of Early Breast Cancer Screenings

March 5th 2024

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Dr Jagsi on the Implications of the IDEA Trial For Patients With Breast Cancer

March 4th 2024

Reshma Jagsi, MD, DPhil, discusses the implications of the IDEA trial for patients with breast cancer.

Dr Shen on the Utility of ARX517 in mCRPC

March 4th 2024

John Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.

Dr Feldman on the Importance of the TRANSCEND CLL 004 Trial in CLL/SLL

March 4th 2024

Tatyana Feldman, MD, discusses the TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

March 4th 2024

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Dr Lencioni on Unmet Needs in Unresectable HCC

March 4th 2024

Riccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.

Dr Obeng-Gyasi on the Impact of Social Determinants of Health on Breast Cancer Outcomes

March 1st 2024

Samilia Obeng-Gyasi, MD, MPH, discusses the impact of social determinants of health on breast cancer care outcomes.

Dr Phillips on the Treatment Landscape for Patients With MCL

March 1st 2024

Tycel Phillips, MD, discusses the landscape of treatment for patients with mantle cell.

Dr Jagsi on the Implications of the IDEA Trial for Radiotherapy Omission in Breast Cancer

March 1st 2024

Reshma Jagsi, MD, Dphil, discusses caveats when interpreting long-term results from the IDEA trial of radiotherapy omission in breast cancer.

Dr Mohindra on Updates in SCLC Management

March 1st 2024

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

Dr Pedersen on Updates in mCRC Management

March 1st 2024

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

Dr Childs on Treatment Updates in mHSPC

March 1st 2024

Dan S. Childs, MD, discusses the evolution of the treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Dr Rini on the Utility of Belzutifan in RCC

March 1st 2024

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Dr Shore on Ongoing Research With Radioligand Therapy in nmCSPC

March 1st 2024

Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.

Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer Care

March 1st 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

Dr Wisinski on Treatment Developments in HR+/HER2– Breast Cancer

February 29th 2024

Kari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.